BORIS/CTCFL, a paralogue of the chromatin architectural protein CTCF, is a member of the cancer-testis antigen family, normally present in the testes. BORIS is expressed in various tumours, including prostate cancers, however the function of BORIS in cancer cells is not well defined. The androgen receptor (AR) plays a critical role in the normal development of a human prostate gland and pathogenesis of prostate cancer. In our previous study we described a positive correlation between 
Introduction
BORIS (Brother of the Regulator of Imprinted Sites), also called CTCFL for "CTCF-like", is a paralogue of the transcription factor, CTCF [1] [2] [3] [4] , a ubiquitous protein playing important roles in the regulation of transcription [5, 6] , chromatin insulation [7, 8] and global nuclear organization [9] [10] [11] .
The N-and C-terminal domains of BORIS and CTCF are distinct, whereas the central 11 zinc-finger DNA binding domain in these proteins is almost identical [1, 2] . It is therefore expected that BORIS and CTCF have the ability to bind to similar sequences supported by the genome-wide ChIP-Seq data [12] , however recent studies revealed more complex patterns in BORIS binding [13] . BORIS expression is restricted to the testis [1, 2] , but it is aberrantly activated in various human cancers, including prostate cancer [14] [15] [16] [17] [18] [19] . BORIS functions have not been fully investigated, but it has been reported that BORIS is important for epigenetic reprogramming occurring in the germ cells during development [1, 2, 12, 20, 21] . Furthermore, epigenetic changes introduced by BORIS, have been reported to cause DNA and histone demethylation, chromatin remodelling and activation of transcription of various genes, including cancer genes [22] [23] [24] [25] [26] [27] [28] . BORIS has been linked to cell proliferation [29] and cancer stem cells and "stemness" gene expression [30, 31] . However, a defined function of BORIS in cancer cells still remains debatable [17, 32, 33] .
Our previous study revealed an association between BORIS and Androgen Receptor (AR) whereby the elevated levels of BORIS in prostate cancer cell lines and tumours not only correlated with high AR levels in prostate cancer cells, but BORIS could stimulate expression of the endogenous AR gene [18] .
AR is a member of the nuclear receptor superfamily [34] activated by androgens, in particular testosterone, primarily produced by the testes with a small contribution from the adrenal glands [35] , which in prostate cells is converted into a more active hormone, dihydrotestosterone (DHT) [36] . In the absence of the ligand, the AR is located primarily in the cytoplasm, however following the interaction of DHT with AR, the ligand-induced receptor translocates to the nucleus where it forms a homodimer and binds to the androgen response elements (AREs) of the androgen-sensitive genes [37] . Many AR target genes have been identified and are known to be involved in the maintenance of prostate growth and development [38] [39] [40] [41] . The AR mediates various functions of androgens essential for cell viability, proliferation and invasion [42, 43] . It is also one of the key factors in the pathogenesis of androgen dependent prostate cancer (ADPC), which initially relies on the AR signalling pathways [44, 45] and hence the androgen-ablation therapy has been the most common treatment for ADPC patients [46, 47] .
However, ADPCs eventually become androgen-independent and ultimately progress to more aggressive androgen independent prostate cancer (AIPC). The molecular mechanisms of these phenomena are not well understood, however a wide range of genetic and epigenetic mechanisms have been implicated in the development of refraction to androgens [48] [49] [50] . Epigenetic changes (e.g. AR methylation, chromatin modifications, transcriptional control) are of particular interest as they can be reversed [51, 52] . It is therefore important to investigate the molecular events involved in the epigenetic regulation of the AR, in particular the role of transcription factors in these processes. For example, LEF1 and YB-1 were reported to activate [53, 54] and p53 to repress AR [55] . Various functional elements have been identified and binding sites for more than 20 transcription factors mapped in the AR promoter region [49] .
The correlation found between BORIS and AR expression in prostate tumour tissues [18] led to the hypothesis that BORIS can be involved in prostate tumour progression as a direct transcriptional regulator of AR. In the present study we demonstrate that BORIS plays an important role in the activation of the AR gene in ADPC and AIPC cells and proposed a model of epigenetic regulation of AR by BORIS.
Materials and Methods

Cell Lines
Prostate cell lines used in this study were the AR-positive and androgen dependent prostate cancer (ADPC) cells, LNCaP and VCaP; AR-negative and androgen independent prostate cancer (AIPC) cells DU145, partially AR-positive and androgen independent prostate cancer (AIPC) cells, PC3, and AR-negative and androgen independent benign prostate cells, BPH-1. Cells were maintained in RPMI 1640 medium supplemented with L-Glutamine (PAA-GE Healthcare), 50µg/ml Gentamicin (Life Technologies-Invitrogen) and 10% foetal bovine serum (Biosera).
Transient transfections with plasmid DNA and siRNA
The expression vectors (pCMV6-BORIS, pCI-CTCF, pEGFP-BORIS) used in transient transfections have been previously described. Transient transfections were performed using a calcium phosphate transfection protocol [56] . Hs_CTCF_4 siRNA (Qiagen, Manchester, UK), BORIS SMARTpool siRNA (Dharmacon, Epsom, UK) and non-target siRNA (Dharmacon, Epsom, UK) were used for transfections at a concentration of 50 pM. Cells were seeded at a density of 1.2 x 10 5 and transfected on the following day with siRNA and DharmaFECT2 (Dharmacon) according to the manufacturer's protocol.
Western-blot analysis
For Western blot analysis, lysates from cells were prepared according to Klenova et al [57] with modifications. The primary antibodies were used at the following dilutions: mouse anti-BORIS monoclonal antibody (clone A47, MABE 1125, Millipore), 1:1000; mouse anti-Androgen Receptor and Goat anti-rabbit IgG-HRP (Abcam) (used at 1:15,000 dilution). Detection was performed with enhanced chemiluminescence reagent (Interchim) according to the manufacturer's instructions.
Immunofluorescence staining
Immunofluorescence staining was performed on prostate cancer cells transiently transfected with pEGFP-BORIS expression vector as previously described followed by incubation with 100 nmol of DHT (5α-Androstan-17β-ol-3-one) (SIGMA). After 24 hours of DHT treatment, cells were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton X-100 in 1xPBS, blocked with 2% normal goat serum in 1xPBS: 0.05% Tween: 1% BSA, incubated with the mouse anti-AR antibody (AR441-Abcam; Ab dilution 1:100) and then with the TRITC-labelled anti-mouse IgG antibody (Southern Biotech, Antibody dilution 1:200). The cells were mounted on the microscope slides with
Fluoro-Gel mounting media containing DAPI (4',6-diamidino-2-phenylindole dilactate) (Interchim).
Images were taken at x60 magnification using Nikon Eclipse Ti microscope. Staining of cells expressing EGFP-BORIS without DHT exposure was also performed to visualize the differences in AR localization under the effect of DHT.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were performed from cross-linked cells (∼1 x 10 6 ) using Protein A agarose/salmon sperm DNA beads (Millipore) for rabbit (IgG) polyclonal anti-CTCF antibody (Millipore), rabbit polyclonal anti-H3K4me3 (active chromatin) (Millipore), rabbit polyclonal anti-H3K27me3 (repressive chromatin) (Millipore) and Protein L agarose beads (Thermo Scientific) for mouse monoclonal (IgM) anti-BORIS N-terminal antibody. Protein L Agarose beads were treated with 1 µg sheared salmon sperm DNA (Ambion) according to the manufacturer's instructions. Cross-linking and immunoprecipitation procedures were followed as described before.
Immunoprecipitated DNA was extracted with phenol/chloroform and ethanol precipitated. Real-time PCR was carried out in triplicate using 2 µl of the immunoprecipitated DNA sample and input DNA and 300 nM primers diluted to a final volume of 25 µl in SensiMix Plus SYBR (Quantace Amplification, data acquisition, and analysis were carried out using the Bio-Rad CFX Real-Time PCR (Bio-Rad Laboratories). The comparative C t method was used to assess relative changes in mRNA levels [58] ; calculations were made according to Pfaffl [58] . Primers and conditions for RTqPCR are described in the Supplemental Table 2 .
DNA methylation analysis using methylation dependent restriction enzyme McrBC
A restriction enzyme, McrBC (NEB) was used to analyze DNA methylation within the AR promoter. It specifically cleaves DNA containing methyl cytosine preceded by a purine nucleotide (A or G) [59, 60] . The reaction consisted of 500ng of genomic DNA, 5 units of McrBC enzyme, 1x NEB buffer 2, 1x
BSA, 1mM GTP and water in a total reaction volume of 50µl. The reaction was incubated at 37°C for 16 hrs followed by PCR performed on digested and undigested DNA, using the AR promoter specific 
Statistical Analysis
Statistical analysis was carried out using unpaired Student's T-test. A significant value was detected when the probability was below the 5% confidence level (P < .05).
Results
AR gene and protein expression analysis in prostate cancer cells with manipulated levels of BORIS and CTCF
We previously reported that expression from the endogenous AR gene increased in the AR positive and androgen dependent prostate cancer (ADPC) cells, LNCaP, transiently transfected with the plasmid containing BORIS cDNA [18] . We extended this analysis by examining whether BORIS will be able to activate AR in the AR-negative and androgen independent prostate cancer (AIPC) cells, DU145. We also aimed to assess the effects of a BORIS paralogue, CTCF, on AR since both, CTCF and BORIS, are present in prostate cancer cells. For these experiments, the levels of BORIS and CTCF in LNCaP and DU145 cells were transiently increased or decreased, using expressing vectors or siRNAs, respectively. Reduction in CTCF caused up-regulation in the AR mRNA levels, i.e. the effects opposite to BORIS depletion in both cell lines. However, very little or no difference in AR expression was observed in samples with high levels of CTCF ( Figure 1C , left panel). The changes in CTCF mRNA in cells depleted of CTCF were significant, however, only a very small change in the CTCF mRNA levels were detected in samples transfected with pCI-CTCF ( Figure 1C , right panel). This is surprising given that the ectopic CTCF protein was present at high levels (see below).
Next, the assessment of AR, CTCF and BORIS expression at the protein levels was carried out.
As shown in Figure 1B where, for example, mRNA half life could be much shorter whereas protein stability higher (this is further considered in the Discussion section).
The amounts of the AR protein were also found to be affected by CTCF in both LNCaP and DU145 cells, whereby depletion from CTCF resulted in the increase of the AR protein and vice versa ( Figure 1D ). Notably, although the AR protein was not present in the control DU145 cells, it appeared in cells depleted from CTCF. These effects were more pronounced at the protein level, which implies that in these cells CTCF mRNA may be much less stable than the CTCF protein.
In summary, the analysis of the AR expression at the mRNA as well as protein levels suggest that AR is positively regulated by BORIS and negatively regulated by CTCF, although the latter was demonstrated only in CTCF knock down experiments. The possibility of re-expression of AR in DU145 (AIPC) cells is significant because it may be exploited in the treatment of hormone resistant prostate cancers.
Immunofluorescence analysis of AR in ADPC and AIPC cells transfected with pBORIS-EGFP
plasmid DNA in the presence and absence of DHT.
The aim of our next experiments was to investigate whether the introduction of the ectopic BORIS would result in the production of nuclear AR upon androgen stimulation, which is one of the prerequisites for AR protein to function as the ligand-dependent transcription factor [38] . The response to DHT in LNCaP and DU145 cells was tested prior to these experiments demonstrating, as expected, the increased levels of AR in LNCaP and no AR induction in DU145 cells (Supplemental Figure 2) . 
Analysis of expression from the AR-responsive genes in prostate cancer cells containing ectopic BORIS.
To further confirm AR functionality, expression levels of genes regulated by (PSA and TMPRSS2) in BORIS-over expressing ADPC and AIPC cells were analyzed. Prostate Specific Antigen (PSA) and Transmembrane protease, serine 2 (TMPRSS2) are well characterized AR target genes associated with prostate cancer growth [61] and are known to be up-regulated by AR in the presence of DHT in ADPC cells [62] [63] [64] . On the other hand, very low or no expression of PSA and TMPRSS2 have been reported in AIPC cells such as PC3 and DU145 that can be explained by the lack of functional AR in these cells [63, 65] . In our experimental context, these genes represent suitable candidates to assess the androgen-dependent AR activity.
A panel of cell lines used in these experiments included two ADPC (VCaP, LNCaP), two AIPC (PC3, DU145) and AR-negative benign prostate hyperplasia (BPH-1) cells. As expected, the ADPC were positive for AR mRNA and the appearance of the PSA and TMPRSS2 mRNA was observed in these cells treated with DHT, whereas three other cell types cells were AR, the PSA and TMPRSS2 Our results suggest that BORIS over expression not only restored AR expression in AIPC cells but also produced a functional AR that was able to regulate expression of target genes in the presence of DHT. However no PSA and TMPRSS2 mRNAs were observed in BORIS-over expressing BPH-1 cells; this is addressed further in the Discussion section of this paper.
Analysis of the ChIP-seq data for CTCF binding in the human AR gene using the UCSC genome browser.
The AR gene in DU145 and PC3 is known to be silenced due to promoter hypermethylation [66, 67] . We hypothesized that the AR re-activation could be due to epigenetic changes introduced by Figure 4B ). The enrichment in CTCF binding was more pronounced at the AR CTS-1 and AR CTS-2 than at other AR CTSs and was observed in a wide range of cell lines deposited in the USCS genome browser (Supplemental Figure 6) . The AR CTS-1 and AR CTS-2 contain sequences that comply with the conserved 20-mer CTCF consensus binding motif described in previous reports [7, 69] ( Figure 4C ). Due to their ability to bind the same CTSs, the AR is likely to be regulated by both, CTCF and BORIS, competing with each other for some or all of the six AR CTSs, although the AR CTS-1 and AR CTS-2 may be more important for the AR regulation than other CTS due to their proximity to the AR promoter region. 
BORIS and CTCF interact differentially with the
Discussion
In this study we aimed to investigate a role of BORIS in regulating the Androgen Receptor (AR), one of the major genes vital for normal prostate function and for the initiation of prostate cancer development. Tumours, initially dependent on androgens (ADPCs) slowly progress to more aggressive androgen independent prostate cancers (AIPCs). Evidence exist that a modest increase in AR mRNA is the only change consistently associated with this progression and the development of resistance to antiandrogen therapy [71, 72] . BORIS is likely to play a key role in these processes due to its ability to positively regulate the AR gene expression (this report), in addition to correlation between higher levels of BORIS with increased AR and more aggressive disease described in our previous study [18] .
A wide range of genetic and epigenetic mechanisms have been implicated in the development of the AIPCs [48] [49] [50] , negative for AR mRNA and protein in some tumours but increased in others [73] .
Epigenetic changes are of particular interest as they can be reversed and cells then may restore their sensitivity to anti-androgens if the normal AR gene is silenced. Indeed, treatment with demethylating chemicals, such as 5-aza-20-deoxicytidine, has been successful in partial re-activation of AR in AIPC cells [67] . A known association of BORIS with the re-setting of genome methylation during early embryonic male germ cell development [1, 2] Figure 1 ). Taken together, these findings indicated that there may be functional interplay between CTCF and BORIS in the regulation of AR, which is further discussed below. In general, we noted the lack of correlation between the AR mRNA and the AR protein levels for all three mRNA/protein pairs (AR, CTCF and BORIS) (Figure 1 ). This phenomenon may be explained by differential stability of mRNA and proteins, which may also depend on cell context, with broader variation for proteins than for mRNA, whereby the half-life of different proteins spans from minutes to days compared to 2-7 hours for mRNA [74] .
The AR produced in AIPC cells over-expressing BORIS was biologically active by several criteria: sensitivity to DHT, translocation into the nucleus after treatment with DHT, and activation of the AR-dependent genes, PSA and TMPRSS2. The AR produced in DU145 cells containing ectopic BORIS-EGFP was translocated to the nucleus of these cells after DHT treatment, but not in the with and without DHT treatment, had no effect on PSA and TMPRSS2 in BPH-1 cells ( Figure 3 ) and AR expression (data not shown), suggesting a different mechanism of the AR silencing, which may be due to genetic changes (e.g. absence of AR or a large deletion in the gene) or reflect a possible BPH-1 origin from AR-negative prostate stem cells [78] .
Since BORIS shares the same DNA binding domain with CTCF, we reasoned that CTCF binding sites (AR CTSs) identified within the AR gene using bioinformatics analysis of the ChIP-Seq (Figure 4 ) may also bind BORIS. Five of the identified six AR CTSs are positioned in introns, whereas AR CTS-1 is localized in exon 1. Such intragenic positioning of the CTSs is not surprising given that a large proportion of CTSs are reported in gene regions other than promoter and 5' UTRs [69, 79] .
Furthermore, the concept of the spread of regulatory elements throughout the genome regions, intraand intergenic, has been generally accepted [80, 81] . The presence of ectopic BORIS correlated with the reduction of methylation in the AR promoter in both ADPC and AIPC cells ( Figure 6 ). Such reversible epigenetic changes (hypo-or hypermethylation) affecting gene regulation are common in cancer cells [86] . Studies using haematological and solid tumours have reported a small subset of dedifferentiated cells that are capable of developing stem cell phenotype; they were more likely to be associated with DNA hypomethylation [87, 88] .
ChIP analyses of the AR
Interestingly, expression of BORIS has been associated with proliferation and erasure of methylation marks during male germ-line development [2] and with hypomethylation in cell lines and tumours [22, 89] .
Our findings suggest the importance of BORIS in the epigenetic regulation of AR function in prostate cells, summarized in the model presented in Figure 8 . The direct competition between CTCF and BORIS for binding to the AR CTSs may explain the changes in the AR activity (Figure 8 ), however the AR regulation by CTCF/BORIS may be more complex and involve other transcription factors regulated by CTCF/BORIS including negative effects of CTCF on BORIS expression [21, 90] . Since AR is associated with the development of more aggressive prostate cancer [45] , BORIS function as the transcriptional activator of AR would generally support tumour progression, whereas CTCF which inhibits growth of prostate cancer cells can counteract such influences. These antagonistic features of BORIS and CTCF have been reported previously, however this mode of function may be limited to a certain subpopulation of the DNA targets [13] and the AR gene is likely to belong to this category. It should be noted that the ability of BORIS to activate AR is likely to be restricted to certain stages in the prostate tumour progression. When the androgenindependent state is established in the process of tumour evolution, the levels of endogenous BORIS may not be sufficient to activate the epigenetically silenced AR gene. However, re-activation of AR may be possible if BORIS levels in the cells increase. In the context of this model, stimulation of BORIS expression can be used to re-sensitize AIPC cells so that they can be treated with anti-androgens. It needs to be mentioned that the proposed model is mostly relevant to a subgroup of the AIPC in which the AR gene is epigenetically silenced. It is therefore important to determine the molecular basis of the androgen independency to design appropriate treatment strategies. Finally, whereas this study was focused on the AR as a specific regulatory target of BORIS in prostate cells, it should be acknowledged that as a global transcriptional factor BORIS has wider effects on cellular processes, in particular supporting signalling pathways associated with cell survival and proliferation. The genome-wide expression analysis of prostate cancer cells with manipulated levels of BORIS and CTCF will be published in a separate article (Y.Hari-Gupta, manuscript in preparation).
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